Peptinovo Biopharma, LLC was founded to create a novel, low-cost targeted nanoparticle formulation that makes chemo drugs safer and more effective. The company has completed in vivo concept verification. Founders have supported the company investment to date. 

Financial Projection
The company is seeking outside investment as well as strategic partnerships. We are currently raising $1.5M with a $3.5M follow on. Funds will be used for development, pre-clinical testing, and additional IP filing. A second priced round will fund Phase 1 human trials. The company is also seeking non-dilutive NIH SBIR grants, plus a partnership and grants with leading cancer foundations and internal NIH/NCI faculty.

Intellectual Property: Foundational patent was issued in January 2020 and additional provisional have been filed. Broad PCT coverage and broad-based US filing.

• Re-patents blockbuster drugs - extends patent life 10 + yrs
• Next generation of Paclitaxel - $1.5B in opportunity sales and possible $30 to $60B increase in market valuation for acquiring partner
• Platform - starts with one chemotherapy in one cancer, expands to many chemotherapies in many cancers; multiple exit opportunities
• Benchmark deals approach $2 to $3B per exit - - plus royalty payments

• New delivery method for proven chemotherapies - no new molecule development risk
• Issued patent January 2020 - other Provisionals filed
• Promising in vivo results to reduce neuropathy -  enhances delivery of chemotherapeutic agent to tumors selectively
• Low cost of goods and manufacturing to meet a market price point - proven scalable manufacturing, non-toxic materials, safe delivery mechanism
• Platform for drug delivery based on well known GRAS materials  - 505(b)(2) regulatory pathway

We welcome opportunities to collaborate with biopharmaceutical companies that wish to take advantage of our platform chemotherapy nanoparticle technology.

If you are interested in exploring investment or partnership opportunities with Peptinovo Biopharma, please contact:

Steve Tokarz, MBA
Acting CEO
steve.tokarz@cantileverbp.com

Peptinovo is currently supported by Cantilever Investors and Cantilever Business Partners as well as Alligator Holdings, LLC, a growing group of manufacturing and technology companies focused on innovative product and service development. The company is also a member of MichBio and has been awarded Business Accelerator Funding from the MEDC (Michigan Economic Development Corporation).